Measurable Residual Disease
Measurable Residual Disease - Related Videos
09:57
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
0 Views •
Cited by 38 •
2018
Detection of minimal or measurable residual disease (MRD) is an important prognostic biomarker for refining risk assessment and predicting relapse in acute myeloid leukemia (AML). These comprehensive guidelines and recommendations with best practices for consistent and accurate identification and detection of MRD, may aid in making effective AML treatment decisions.
01:26
Residual Stresses
0 Views •
2024
Residual stresses reside in a structure even after removing the original stress inducer. This phenomenon often arises from varied plastic deformations across different parts of a structure. Consider a rod stretched beyond its yield point. It will not regain its original length due to permanent deformation. Even after load removal, the rod does not entirely lose stress because of uneven plastic deformations, resulting in residual stresses. The computation of these stresses in structures is...
01:07
Residual Plots
0 Views •
2023
A residual plot is a statistical representation of data used to analyze correlation and regression results. It helps verify the requirements for drawing specific conclusions about correlation and regression. To obtain the residual plot, first, the residual for each data value is calculated, which is simply the vertical distance between the observed and the predicted value obtained from the regression equation. When the residual values are plotted against the variable x, it is called a residual...
03:20
Measuring Constipation in a Drosophila Model of Parkinson's Disease
0 Views •
Cited by 1 •
2023
This protocol presents an assay for modeling constipation in an alpha-synuclein based Drosophila model of Parkinson's disease.
01:18
Residual Stresses in Bending
0 Views •
2024
In the study of elastoplastic members subjected to bending moments, understanding the loading and unloading phases is crucial for assessing material behavior and structural integrity. During the loading phase, as the bending moment increases, the material initially responds elastically, adhering to Hooke's Law, where stress is directly proportional to strain. When the load exceeds the yield strength, plastic deformation occurs, resulting in permanent strain and deformation that remains even...
FAQs
MRD measurement provides a quantitative indicator of treatment response, rather than relying only on whether routine testing detects disease. A result can therefore contribute to estimating relapse risk and distinguishing levels of response in cancer research. This makes residual disease assessment useful for comparing therapeutic effects and organizing follow-up strategies.
Detection depends on recognizing a disease-associated feature. Multiparameter flow cytometry identifies abnormal immunophenotypes, while polymerase chain reaction and next-generation sequencing can identify genetic sequences or related molecular signals. These approaches measure residual disease through different biological signatures, allowing investigators to align the assay with the cancer-associated target available in a sample.
They provide measurable features that distinguish cancer-associated material from what routine testing may reveal. An abnormal immunophenotype represents an unusual pattern of cellular markers, whereas a genetic sequence supplies a molecular signal for detection. Identifying either type of feature enables sensitive assessment of treatment response and supports quantitative interpretation of residual disease.
An MRD workflow begins by obtaining blood or bone marrow, selecting a detectable cancer-associated target, and applying an assay such as multiparameter flow cytometry, polymerase chain reaction, or next-generation sequencing. The resulting signal is then quantified and considered alongside treatment response or relapse risk. This sequence converts a small residual signal into a research measurement.
Researchers can use MRD measurements as an outcome for assessing how effectively a therapy reduces detectable cancer-associated material. Because the measurement is quantitative, it can complement routine response testing and help compare treatment effects. In cancer research, this provides a more sensitive basis for examining therapeutic performance than routine tests alone may provide.
MRD results can help stratify patients according to the amount of residual disease detected after treatment, linking measurement with differences in relapse risk. They can also inform follow-up strategies by identifying a quantitative response indicator for continued assessment. In this way, MRD connects laboratory findings with decisions about how treatment outcomes are monitored.